What do we do?

The mission of productive areas is to supply the products and services demanded for domestic consumption and exports, contributing to the social and economic well-being of the country, using manufacturing facilities, technologic and non technologic equipment, highly qualified personnel in accordance with current Good Manufacturing Practices (cGMP) to satisfy national and international market demand. The CIGB’s productive areas are continually involved in an intense regulatory activity that includes obtaining Biological Safety Licence Approvals, Pharmaceutical Operation Licence Approvals and Biological Licence Approvals from internal, national and international inspections.

The main activities that are developed in the area are:

  • Fabricaci√≥n de Ingredientes Farmac√©uticos Activos (IFA) / Active phamaceutical ingredient manufacturing
  • Envase y acondicionamiento de productos terminados / Drug products conditioning and packaging
  • Fabricaci√≥n de productos para ensayos pre cl√≠nicos y cl√≠nicos / Drug product manufacturing for preclinical and clinical trials
  • Transferencia de tecnolog√≠as / Technology transfer
  • Contrataci√≥n de servicios productivos / Contracting of productive services
  • Introducci√≥n de nuevos productos al proceso productivo por transferencia de Investigaci√≥n desarrollo / Introduction of new products into the production process for transfer of R-D
  • Inversiones / Investments

The following are the API manufactured at the GEBC facilities:

  • Recombinant Hapatitis B surface antigent (rHBsAg).
  • Synthetic antigen polirribosil ribitol phosphate for Haemophilus influenzae type b vaccine.
  • Recombinant ¬Ķ 2b interferon (rIFN ¬Ķ2b).
  • Recombinant ő≥ interferon (rIFN).
  • Transfer Factor (FT).
  • Recombinant human erythropoietin (rhEPO).
  • Recombinant Granulocyte Colony Stimulating Factor (rG-SCF).
  • Monoclonal antibody CB- Hep1 (CB-Hep1).
  • Plantibody HB-01.
  • Recombinant protein p64k (rP64K).
  • Human recombinant epidermal growth factor (rhEGF).
  • rhEGF for parenteral use.